Person:
GÜRSU, MELTEM

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Organizational Unit
Job Title
First Name
MELTEM
Last Name
GÜRSU
Name
Email Address
Birth Date

Search Results

Now showing 1 - 3 of 3
  • PublicationOpen Access
    COVİD-19 infection in a membranous nephropathy patient treated with rituximab.
    (2020-09-04T00:00:00Z) Elcioglu, Omer Celal; Artan, Ayse Serra; Mirioglu, Safak; Gursu, Meltem; Durdu, Bulent; Koc, Meliha Meric; Okyaltirik, Fatmanur; Gultekin, Mehmet Ali; Kazancioglu, Rümeyza; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; GÜRSU, MELTEM; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA; OKYALTIRIK, FATMANUR; GÜLTEKİN, MEHMET ALİ; KAZANCIOĞLU, RÜMEYZA
    While COVID-19 pandemic continues to afect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
  • PublicationOpen Access
    Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey
    (2022-05-01T00:00:00Z) ÖZTÜRK, Savaş; Gursu, Meltem; Arici, Mustafa; Sahin, Idris; Eren, Necmi; Yilmaz, Murvet; Ozberk, Sumeyra; Sirali, Semahat Karahisar; Ural, Zeynep; Dursun, Belda; Yuksel, Enver; Uzun, Sami; Sipahi, Savas; Dal, Elbis Ahbap; Yazici, Halil; Altunoren, Orcun; Tunca, Onur; Ayar, Yavuz; Oguz, Ebru Gok; Yilmaz, Zulfikar; Kahvecioglu, Serdar; Asicioglu, Ebru; Oruc, Aysegul; Ataman, Rezzan; Aydin, Zeki; Huddam, Bulent; Dolarslan, Murside Esra; Azak, Alper; Bakirdogen, Serkan; Yalcin, Ahmet Ugur; Karadag, Serhat; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; GÜRSU, MELTEM
    Introduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia.
  • PublicationMetadata only
    COVID-19 Infection in Peritoneal Dialysis Patients: A Comparative Outcome Study with Patients on Hemodialysis and Patients without Kidney Disease
    (2022-01-01T00:00:00Z) KAZANCIOĞLU, Rümeyza; Ozturk, Savas; TURGUTALP, KENAN; GÜRSU, Meltem; ARICI, MUSTAFA; ORUÇ, AYŞEGÜL; Ahbap, Elbis; GÖKÇAY BEK, SİBEL; Sengul, Erkan; Ogutmen, Melike Betul; Genek, Dilek Gibyeli; Ayli, Mehmet Deniz; Ayar, Yavuz; Onan, Engin; Karadag, Serhat; AŞICIOĞLU, EBRU; Yazici, Halil; ALTIPARMAK, MEHMET RIZA; TOKGÖZ, BÜLENT; Odabas, Ali Riza; TONBUL, HALİL ZEKİ; Sezer, Siren; Yildiz, Alaattin; ATEŞ, KENAN; KAZANCIOĞLU, RÜMEYZA; GÜRSU, MELTEM
    Objectives: There is limited data about coronavirus disease-19 (COVID-19) characteristics and results in peritoneal dialysis (PD) patients. This study aimed to investigate the characteristics and outcomes among PD patients and compare them with matched hemodialysis (HD) patients and a control group without kidney disease. Methods: We included 18 PD patients and consecutive age- and gender-matched 18 HD and 18 patients without kidney disease (control group) registered into the Turkish Society of Nephrology database including 1301 COVID-19 patients. We compared demographic, clinical, radiological, laboratory data, and outcomes namely intensive care unit (ICU) admission, mechanical ventilation, mortality, and composite outcome (death and/or ICU admission). Results: ICU admission, mechanical ventilation, and mortality rates in PD patients (27.8%, 22.2%, and 22.2%, respectively) and the HD group (16.7%, 11.1%, and 16.7%, respectively) were higher than the control group (11.1%, 11.1%, and 5.6%, respectively), but intergroup comparison did not reveal difference. A total of 11 (20.3%) patients had composite outcome (6 PD patients, 3 HD patients, and 2 patients in the control group). In Cox regression analysis, higher age and higher CRP level were related to increased risk of composite outcome. Adjusted rate of composite outcome in PD group was significantly higher than the control group (P =.050). This rate was similar in HD and control groups (P =.30). Conclusions: Combined in-hospital mortality and/or ICU admission of PD patients with COVID-19 was significantly higher than the control patients. There is a need for careful surveillance of PD patients for infection signs and prompt treatment of COVID-19.